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A B S T R A C T
Nanoparticles (NPs) of three poorly water-soluble BCS class II active pharmaceutical ingredients (APIs) (clo-
zapine (CLO), curcumin (CUR) and carbamazepine (CBMZ) with zeta potentials –28.5 ± 2.5, –33 ± 1.5 and
–13 ± 1.5mV respectively) were produced, stabilized and isolated into the solid state with the help of
Montmorillonite (MMT) clay carrier particles. The nanoparticles of clozapine (27 nm), curcumin (170 nm) and
carbamazepine (30 nm) were produced and stabilized in suspension using a reverse antisolvent precipitation
technique in the presence of ‘as received’ MMT carrier particles (∼30 μm) and/or MMT carrier particles whose
surface had been slightly modified with a cationic protein, protamine sulphate salt (PA). The resulting nano-
particle carrier composites were isolated directly from suspension into a solid state form by simple filtration
followed by air-drying. The API dissolution rates from these dried NP-carrier composites were comparable with
those of the respective stabilized API nanoparticles in suspension up to maximum CLO, CUR and CBMZ loadings
of 23%, 21.8% and 33.3% (w/w) respectively, although surface modification of the MMT carrier particles with
PA was needed for the CLO and CUR NP-carrier composites in order to preserve the fast API nanosuspension-like
dissolution rates at higher API loadings. For both of these APIs, the optimal loading of PA on MMT was around
4mg/g, which likely helped to limit aggregation of the API nanoparticles at the higher API loadings.
Interestingly, no MMT surface modification was needed to preserve fast API dissolution rates at higher API
loadings in the case of the CBMZ NP-carrier composites. This discrimination among the three APIs for carrier
particle surface modification was previously observed in reported studies by our group for three other APIs,
namely valsartan, fenofibrate and dalcetrapib. When examined together, the data for all six APIs suggest a
general trend whereby API nanoparticles with zeta potentials more positive than around −25mV do not require
carrier particle surface modification with PA in order to preserve their fast dissolution rates from NP-carrier
composites at higher API loadings. Thus, this study offers a potentially effective means of transforming poorly
water soluble BCS Class II APIs into fast dissolving solid dosage NP-carrier composites, whereby the surface
properties of the carrier particle can be tuned with prior knowledge of the zeta potential of the API nano-
particles.
1. Introduction
It has been estimated that almost 90% of new API candidates exhibit
poor water solubility [1–3]. Thus, the bioavailability of these APIs is
limited due to their poor solubility and slow dissolution rate [4,5]. APIs
with low solubility are likely to either accumulate in tissue or be
eliminated via a first-pass metabolism in the intestines or liver due to
their high lipophilicity [6]. Various methods have been developed over
the past few years to tackle poor water solubility, for example, cyclo-
dextrin complexation [7], crystal modification [8], solid dispersions
[9], polymeric micelles [10] and lipid-based delivery [11]. Another
highly researched area is formulation by nanotechnology where the size
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of API particles, when decreased to the nanometre range, can sig-
nificantly change the particles’ physical properties. This approach is the
foundation of nanomedicine for pharmaceutical applications [6]. By
downsizing the poorly water-soluble API particles, kinetic character-
istics change, giving rise to new attributes like more rapid dissolution
rates and applications such as dry powder inhalation [6]. Parameters
that affect solubility and dissolution rate are described by the Ost-
wald–Freundlich equation and Noyes-Whitney equation respectively
[12,13,14,15].
API nanoparticles are formed by two major strategies, namely “top-
down” and “bottom-up” approaches. Top-down approaches for nano-
particle formation include wet milling [16–18] and high-pressure
homogenization [19]. Though the top-down approaches are more
common, they have their own limitations, such as difficulty in con-
trolling particle size and morphology, chemical degradation and solid-
state changes of the micronized product [20–23]. They also require
long processing times to reduce the particle size to less than 100 nm
[23].
On the other hand, crystallization-based bottom-up approaches such
as antisolvent precipitation, sono-precipitation or methods based on
microemulsions start with the molecules in solution to directly form
nanoparticles [6]. Such approaches can offer narrow particle size dis-
tributions and greater flexibility for controlling the amorphous or
crystalline form of the API [24]. Relative to top-down mechanical size
reduction processes, bottom-up precipitation/crystallization-based
processes are very fast, less expensive and can be performed at low
temperatures making them suitable for thermolabile APIs [24,25].
However, nanoparticles in suspension are unstable, tending to ag-
glomerate or undergo Ostwald ripening [26] in order to minimize their
excessive surface energy [22]. The use of various stabilizers such as
surfactants, polymers and lipids is critical to the generation of physi-
cally stable nanoparticles by reducing the surface energy of nano-
particles via steric and/or ionic stabilization [22,27]. Although sur-
factants, polymers and lipids can act as temporary stabilizers to retard
the growth process of nanoparticles, prolonged stabilization can only be
achieved by isolating them into a solid-state form [28]. Once isolated,
however, it is important that the nanoparticles remain in the un-
aggregated form to retain their advantages for bioavailability en-
hancement [28,29].
Freeze drying, spray drying and centrifugation are commonly used
methods to convert nanosuspensions to the dried solid state. Although
these methods of drying the nanoparticles have been actively adapted
by the pharmaceutical industry, they have certain limitations, such as
high energy requirements, long processing times, and aggregation of
nanoparticles during drying.
Our group has previously reported a one-step approach for pre-
paring, stabilizing and isolating nanoparticles of valsartan [30], feno-
fibrate [31], dalcetrapib [32] and mefenamic acid [31] into the solid
state with the help of montmorillonite (MMT) or protamine functio-
nalized montmorillonite (PA-MMT) clay as carrier particles, achieving
excellent dissolution rate at API loadings of 33.3%, 9.1%, 20.9% and
4.8% (w/w) respectively. Nanoparticles of these APIs were generated in
suspension via antisolvent precipitation, and carrier particle-mediated
stabilization and isolation of these nanoparticles from suspension into a
solid form was achieved by adding the carrier particles before or shortly
after precipitation, followed by simple filtration and air drying. The
dissolution rates of these APIs from their respective MMT or PA-MMT
nanocomposite solids were shown to be influenced by parameters such
as nanoparticle size, the extent of PA functionalization and the API
loading on the carrier particle system [30,31].
The challenge associated with the MMT stabilized nanoparticles is
one of achieving a high API loading while maintaining the integrity,
stability and excellent dissolution properties of the nanoparticles. The
“API loading” in commercially available tablet/capsules (that is, the
mass of API as a percentage of the total tablet mass: % (w/w)) depends
upon several factors such as the dose required, the choice of excipients
and the API properties in terms of the chemical and physical inter-
ference with the excipients. A review of the commercially available
nanoformulations of Emend and Triglide indicates API loadings of ap-
proximately 25–30% (w/w), while the loading in Zanflex is 3−5% (w/
w). In our published work to date the highest API loading achieved has
been 33.3% (w/w) for valsartan on PA-MMT, while much lower values
(in the range 4–9% (w/w)) were achieved with fenofibrate and mefe-
namic acid. A reasonable interim objective for these API nanocompo-
sites would be 30% (w/w) while still maintaining fast dissolution
properties, although ultimately the target loading depends on the po-
tency and required dose of each particular API.
This study focuses on investigating the effect of protamine in
modifying the zeta potential of MMT and how this modification influ-
ences the ability of the clay to stabilize API nanoparticles with different
Fig. 1. Molecular structures of clozapine, carbamazepine and curcumin.
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zeta potentials at high loadings. A panel of API nanoparticles with
different zeta potentials (Fig. 1) was screened to examine the role of PA
in extending their maximum API loading when present in nano-
composites while maintaining the dissolution behavior of these nano-
particles. In the discussion section of this report we will also in-
corporate data from our previous studies related to fenofibrate [31],
mefenamic acid [31], dalcetrapib [32] and valsartan [30].
2. Experimental
2.1. Materials
Clozapine as free base (CLO,> 98% pure, CCDC NDNHCL01) and
carbamazepine (CBMZ > 98% pure, CCDC CBMZPN01) were gener-
ously supplied by Novartis and used as received. Curcumin (∼78%
pure) was purchased from Sigma Aldrich (Ireland) and was used after
recrystallization from isopropyl alcohol (IPA) to get> 99% pure cur-
cumin; this study will be reported in a subsequent publication.
Montmorillonite K10 (MMT), Pluronic®F-127, protamine sulphate salt
from salmon sperm (PA, approx. 5.1 kDa), methanol (MeOH), hydro-
xypropyl methyl cellulose (HPMC, ∼26 kDa), sodium dodecyl sulphate
(SDS), and polyvinylpyrrolidone K 30 (PVP K 30, 40 kDa) were all
purchased from Sigma Aldrich (Ireland) and were used as received
without further purification.
2.2. Preparation of stabilized nanosuspensions of APIs
Nanosuspensions of the three APIs clozapine (CLO), carbamazepine
(CBMZ) and curcumin (CUR) were produced and stabilized via reverse
liquid antisolvent precipitation by injecting the API dissolved in organic
solvent into water (the antisolvent) containing a suitable water-soluble
polymer stabilizer (Pluronic® F-127, PVP K 30 or HPMC). Process
parameters such as solvent choice, antisolvent-solvent (AS/S) ratio,
choice and concentration of stabilizer in the antisolvent, concentration
of the API in the solvent, stirring rate and temperature were success-
fully optimized, thus allowing for good control over the particle size
distribution of the respective API nanoparticles in suspension. The op-
timized process parameters are summarized in Table 1.
2.3. Preparation of API-MMT and API-PA-MMT nanocomposites
API-MMT nanocomposites of CLO, CUR and CBMZ were prepared
and isolated according to the procedure outlined in the study published
previously by our group [30]. In brief, API-MMT nanocomposites of
CLO, CUR and CBMZ were prepared by promptly injecting 0.3mL of
CLO solution in methanol (50mg/mL), 0.7mL of CUR solution in
acetone (20mg/mL) or 0.3mL of CBMZ solution in methanol (50mg/
mL) respectively into 20mL of an MMT suspension in water (containing
different amounts of MMT ranging from 2.5mg/mL to 10mg/mL). API-
PA-MMT nanocomposites of CLO and CUR were prepared by promptly
injecting 0.3mL of CLO solution in methanol (50mg/mL) or 0.7 mL of
CUR solution in acetone (20mg/mL) respectively into 20mL of an
MMT suspension (2.5 mg/mL) in an aqueous solution of PA (containing
different amounts of PA ranging from 4.2–6.4mg PA/g of MMT). All
antisolvent compositions were equilibrated for 3 h at 25 °C under
continuous stirring of 800 rpm prior to injecting the API solution for
reverse antisolvent precipitation. Following the reverse antisolvent
precipitation, the resulting suspended API-MMT or API-PA-MMT na-
nocomposites were aged for 1min, then filtered using 0.2 μm poly-
vinylidene fluoride (PVDF) membrane filters. The resultant filter cakes
were dried in a fume hood at ambient temperature and pressure for
24 h.
The percentage of CLO, CUR and CBMZ nanoparticles adsorbed onto
the MMT or PA-MMT carrier particles was determined by measuring the
concentration of API in the filtrate on a Shimadzu UV-1800 spectro-
photometer at λ=212, 424 and 284 nm respectively after diluting an
aliquot of the filtrate by a factor of 10 in methanol (except for curcumin
which was diluted in an aqueous solution of 0.3% SDS) to dissolve any
API nanoparticles present.
2.4. In vitro API release studies
In vitro dissolution profiles were obtained for (i) polymer-stabilized
nanosuspensions of clozapine (CLO), curcumin (CUR) and carbamaze-
pine (CBMZ), (ii) dry powdered samples of CLO-MMT, CLO-PA-MMT,
CUR-MMT, CUR-PA-MMT and CBMZ-MMT nanocomposites at different
API loadings and with different degrees of PA functionalization, and
(iii) samples of CLO (as received, particle size ∼ 11 μm), CUR (re-
crystallized, particle size ∼ 6 μm) and CBMZ (as received, particle size
∼ 16 μm) (Supplementary information, Fig. S1). The dissolution studies
were conducted under sink conditions in 100mL of deionized water for
CLO and CBMZ, and 100mL of an aqueous solution containing 0.3%
SDS for CUR, under continuous agitation (300 rpm) at 37 ± 0.5 °C. The
extent of API dissolution of CLO, CBMZ and CUR was measured using a
Shimadzu UV-1800 spectrophotometer at λ=212, 284 and 424 nm
respectively by withdrawing 1mL aliquots at pre-determined time in-
tervals (0.5, 1.5, 3, 5, 10, 15, 30 and 60min) from the bulk solution
with a preheated plastic syringe and filtering through a 0.22 μm pore
preheated polytetrafluoroethylene (PTFE) syringe filter.
2.5. Particle size distribution and zeta potential of API nanoparticles
Particle size distribution and zeta potential measurements of API
nanoparticles were performed on a Malvern Zetasizer Nano ZSP system
using water as the dispersion medium. The particle size distribution
measurements were performed using samples of the polymer-stabilized
API nanosuspensions. The zeta potential measurements were performed
using samples of free (that is, not polymer-stabilized) nanoparticles for
each API; these free nanoparticles were generated via liquid antisolvent
precipitation by injecting the API dissolved in organic solvent into
water (the antisolvent) and then conducting the zeta potential mea-
surement as promptly as possible in order to minimize the extent of
nanoparticle agglomeration.
All samples were equilibrated for 120 s prior to measurement, and
all measurements were taken at 25 °C. Refractive indices of 1.681,
1.416, 1.669 and absorption indices of 0.010, 0.010, and 0.001 were
used to measure the distributions of particle size and zeta potential of
the CLO, CUR and CBMZ nanoparticles respectively. Particle size dis-
tributions were measured by utilizing a dynamic light scattering tech-
nique. Ten measurements were taken per run and each sample was run
3 times. Zeta potentials of the nanoparticles were determined from
electrophoretic mobility by using the Smoluchowski approximation
Table 1
Optimized process parameters for producing the polymer-stabilized nanosuspensions of curcumin, clozapine and carbamazepine.
API Volume and stabilizer concentration of antisolvent Dosing volume and concentration of API solution Temperature (°C) Stirring rate (rpm)
Curcumin (CUR) 20mL of aqueous solution of PVP K 30 (0.3% (w/w)) 0.7 mL of API solution in acetone (20mg/mL) 25 800
Clozapine (CLO) 20mL of aqueous solution of Pluronic® F-127 (0.2% (w/w)) 0.3 mL of API solution in methanol (50mg/mL) 25 800
Carbamazepine
(CBMZ)
20mL of aqueous solution of HPMC (0.4% (w/w)) 0.3 mL of API solution in methanol (50mg/mL) 25 800
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Fig. 2. Comparison of the dissolution profiles in de-ionized water
at 37°C for (a) curcumin (CUR) as received (∼6 μm) with those
for curcumin from the following formulations: PVP K 30-stabi-
lized curcumin nanosuspension and dried CUR-MMT nano-
composites (NCs) with the indicated curcumin loadings (% (w/
w)), (b) clozapine (CLO) as received (∼11 μm) with those for
clozapine from the following formulations: Pluronic® F-127-sta-
bilized CLO nanosuspension and dried CLO-MMT nanocompo-
sites (NCs) with the indicated clozapine loadings (% (w/w)), and
(c) carbamazepine (CBMZ) as received (∼16 μm) with those for
carbamazepine from the following formulations: HPMC-stabilized
carbamazepine nanosuspension and dried CBMZ-MMT nano-
composites (NCs) with the indicated carbamazepine loadings (%
(w/w)).
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[33]. The samples were filled into disposable folded capillary cells and
equilibrated for 120 s prior to measurement and each measurement
were taken at 25 °C. Forty measurements were taken per run and each
sample was run 10 times with a delay of 5 s between each run.
Number based particle size distributions of as received clozapine,
carbamazepine and recrystallized curcumin were measured using a
Malvern Morphologi G3SE microscopic particle characterization system
(Malvern Instruments, Malvern, UK). Powdered samples were dry dis-
persed using the system’s automated sample dispersion unit (SDU) with
an area of 5541 mm2 onto a glass plate (180×110mm) with an in-
jection pressure of 4.0 bar, an injection time of 10ms and a setting time
of 60 s. A diascopic light was passed from the bottom of the glass plate
with automatic light calibration intensity using a set value of 80 and an
intensity tolerance of 0.20. A range of particle sizes from 1 μm to
200 μm was analyzed using the 10× (Nikon TU plan ELWD) magnifi-
cation optics selection.
2.6. Differential scanning calorimetry
Differential scanning calorimetry (DSC) was carried out using a
PerkinElmer Pyris 1 DSC instrument using platinum pans with pinholes
(as manufactured), sealed by a crimping press. Experiments were car-
ried out under a nitrogen environment (30mL/min) in the temperature
range 30–170 °C at a scan rate of 10 °C/min. The instrument was cali-
brated using samples of indium and lead.
2.7. Power X-ray diffraction (PXRD)
Powder X-ray diffractograms were recorded in reflection mode
using an Empyrean diffractometer (PANalytical, Philips) with Cu Kα1
radiation (λ=1.5406 Å) at 40mA and 40 kV. Scans were performed
between 5 and 40° 2θ at a scan rate of 0.026° 2θ/min and a step size of
112.97 s per step, on a flat stage that was spinning at 4 rpm.
3. Results
3.1. Particle size distributions of the polymer-stabilized API nanoparticles
Using the optimized process parameters shown in Table 1, nano-
particles of CLO, CUR and CBMZ with particle sizes of 27 ± 0.5,
173 ± 0.8 and 30 ± 0.5 nm respectively were obtained immediately
after their precipitation from their supersaturated solutions in the
presence of soluble polymeric stabilizers, Pluronic® F-127, PVP K 30
and HPMC respectively (Supplementary information, Fig. S2).
It was not necessary to use soluble stabilizers while making API-
MMT and API-PA-MMT nanocomposites (Section 2.3) because the na-
noparticles adsorbed onto the MMT carrier particles immediately after
precipitation. It appears that the MMT and PA-MMT carrier particles
alone were able to stabilize the nanoparticle size and surface area (as
indicated by the subsequent fast API dissolution rates for the API-MMT
and API-PA-MMT nanoparticle-carrier composites, Section 3.3).
3.2. Attachment of API nanoparticles onto MMT/PA-MMT carrier particles
Attachment of API nanoparticles onto the MMT/PA-MMT carrier
particles was confirmed by the clear filtrate obtained following filtra-
tion (through 0.22 μm PVDF membrane filters) of the respective API
nanocomposite suspensions, and thereafter by checking the API con-
centration in the filtrates by UV–vis spectroscopy. The concentration of
API in the filtrate confirmed that> 99% of the CLO, CUR and CBMZ
had adsorbed onto the MMT/PA-MMT carrier particles at loadings of
9.09%, 21.8% and 33.3% (w/w) respectively. The extent to which CLO,
CUR and CBMZ nanoparticles adsorbed onto the MMT/PA-MMT carrier
particles reduced to 87.4%, 81.8% and 88% when the CLO, CUR and
CBMZ loading was increased to 23%, 31.8% and 42.8% (w/w) re-
spectively (Supplementary information, Fig. S3).
The functionalization of MMT with PA does not seem to effect the
amount of API which can be accommodated when compared to the
unfucnctionalized surface (Supplementary information, Fig. S3).
3.3. Dissolution studies of API-MMT nanocomposites
The dried API-MMT nanocomposite solids of CLO, CUR and CBMZ
were suspended in deionized water at 37 °C and their API dissolution
profiles were established. Fig. 2 compares the dissolution profiles of the
three APIs from their respective API-MMT nanocomposites with the
dissolution profiles of the APIs for (i) their respective crystalline forms,
and (ii) their respective polymer-stabilized nanosuspensions. The dis-
solution profiles for all three APIs from their respective MMT nano-
composite solids were considerably better than the profiles for their
respective crystalline forms in terms of the rate of API dissolved. Fur-
thermore, the dissolution profile for CUR and CLO from the 9% and
6.5% (w/w) loaded CUR-MMT and CLO-MMT nanocomposite solids
respectively were similar to the profiles for their polymer-stabilized
nanoparticles in suspension. The comparison becomes less favorable at
higher loadings for both APIs (Fig. 2(a) and (b)). By contrast, the dis-
solution profiles for CBMZ from CBMZ-MMT nanocomposite solids up
to an API loading of 33.3% (w/w) were comparable with the profile for
CBMZ from its HPMC-stabilized nanosuspension (Fig. 2(c)).
An assessment of the long-term stability of the dried nanocomposite
solids for CLO, CUR and CBMZ is presently in progress and will be re-
ported in a subsequent publication. The assessment is being conducted
in a similar manner to a previously reported stability study by our
group, wherein dried valsartan nanocomposite solids stored at ambient
temperature for ten months displayed similar dissolution profiles to
freshly prepared dry valsartan nanocomposite solids and freshly pre-
pared polymer-stabilized valsartan nanosuspensions [30].
3.4. Charge modification of MMT with PA
There was a noticeable deterioration in the API dissolution profiles
for CUR-MMT and CLO-MMT nanocomposites at higher API loadings of
21.8% and 23% (w/w) respectively. This may be due to aggregation of
the API nanoparticles on the MMT surface resulting in less available
nanoparticle surface area for dissolution. In order to improve the dis-
solution rate of CUR and CLO at higher loadings, the surface charge of
MMT was modified by the adsorption of the cationic protein protamine
(PA) prior to the antisolvent precipitation step by following the pro-
cedure outlined in the previous studies from our group [30,31].
In these previous studies, a loading of PA on MMT of around
3−5mg/g was found to be optimum for maintaining nanosuspension-
like dissolution profiles for valsartan (Val), fenofibrate (FF) and mefe-
namic acid (MEF) nanoparticles at higher loadings from Val-PA-MMT
[30], FF-PA-MMT [31] and MEF-PA-MMT [31] nanocomposites re-
spectively, possibly due to the PA’s ability to reduce the extent to which
the API nanoparticles aggregated on the MMT’s surface.
Free nanoparticles of CLO, CUR and CBMZ possess negative zeta
potentials of −28.5 ± 2.5, −33 ± 1.5 and −13 ± 1.5mV respec-
tively (Supplementary information, Fig. S4). Unmodified MMT also
possesses a negative zeta potential of −31 ± 1mV, which can be
tuned from negative to positive by adsorption of increasing amounts of
PA [30].
In the case of CLO-MMT nanocomposites, the maximum loading at
which a nanosuspension-like dissolution profile was preserved was
6.5% (w/w) when the MMT was not functionalized with PA. However,
having functionalizing the MMT with PA prior to antisolvent pre-
cipitation, the maximum loading at which a nanosuspension-like dis-
solution profile was preserved for CLO-PA-MMT nanocomposites in-
creased to 23% (w/w) (Fig. 3(a)). Similarly for the curcumin system, by
functionalizing MMT with PA, the loading of CUR at which a nano-
suspension-like dissolution profile could be preserved increased from
9% to 21.8% (w/w) (Fig. 3(b)). By contrast, the dissolution profile for
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CBMZ from CBMZ–MMT nanocomposites at loadings up to 33.3% (w/
w) was already comparable with that for carbamazepine from its
polymer-stabilized nanosuspension (Fig. 2(c)), and modification of
MMT with PA made no meaningful improvement (data not shown).
The optimal PA coverage on MMT in both cases (CLO and CUR) was
4.2 mg PA/g of MMT (Fig. 3). The zeta potential of PA-MMT at this
coverage was −29 ± 0.7mV, while the zeta potentials at coverages of
5.8 and 6.36mg of PA/g of MMT were −27.3 ± 0.4 and
−26 ± 0.7mV respectively (Supplementary information, Fig. S5).
Thus, only a very small change in zeta potential (−31 ± 1mV to
−29 ± 0.7mV) of MMT is required to preserve the API nanosuspen-
sion-like dissolution rates at higher loadings.
3.5. Solid-state characterization
The solid states of the API-MMT nanocomposites were studied via
PXRD and DSC. Fig. 4 shows the PXRD patterns of the three ‘as re-
ceived’ APIs and the related API-MMT nanocomposites. As received
clozapine, recrystallized curcumin and as received carbamazepine show
characteristic high-intensity diffraction peaks, as do the diffractograms
for 23%, 21.8% and 33.3% (w/w) physical mixtures of CLO-MMT, CUR-
MMT and CBMZ-MMT respectively; the physical mixtures were pre-
pared by mixing the required amount of as received API and MMT by
spatula. No trace of the typical crystalline peaks of clozapine and cur-
cumin were observed for the CLO-MMT and CUR-MMT nanocomposites
respectively indicating the X-ray amorphous nature of the clozapine
and curcumin nanoparticles. In the case of CBMZ-MMT nanocompo-
sites, the PXRD showed peaks corresponding to Form III carbamazepine
when the loading was increased to 33.3% (w/w) (Fig. 4(c)). However,
the intensity of the peaks was somewhat less than that of the corre-
sponding CBMZ-MMT physical mixture with an equivalent composi-
tion, likely indicating a considerable degree of amorphous component
in the CBMZ−MMT nanocomposite.
Additionally, DSC was used to further confirm the solid form of the
curcumin, clozapine and carbamazepine nanoparticles adsorbed onto
the MMT carrier particles. The DSC patterns of as received curcumin
and clozapine (Fig. 5) showed a sharp endothermic peak at
181.6 ± 0.2 and 193.05 ± 0.5 °C respectively corresponding to their
melting temperatures. In the case of as received carbamazepine, an
endothermic peak was observed at 176.4 ± 0.5 °C which indicates the
melting of Form III which spontaneously recrystallized to Form I in-
dicated by an exothermic peak at 177.6 ± 0.3 °C [34]. A sharp
Fig. 3. Comparison of the dissolution profiles in de-ionized water at 37°C of (a) clozapine (CLO) from the following formulations: Pluronic® F-127-stabilized CLO
nanosuspension, dried CLO-MMT nanocomposite (NC) (23% (w/w)) and dried CLO-PA-MMT nanocomposites (23% (w/w)) at different PA coverages, and (b)
curcumin (CUR) from the following formulations: PVP K 30-stabilized curcumin nanosuspension, dried CUR-MMT nanocomposite (NCs) (21.8% (w/w)) and dried
CUR-PA-MMT nanocomposites (21.8% (w/w)) at different PA coverages.
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Fig. 4. PXRD patterns of (a) as received clozapine (CLO), MMT, a 23% (w/w) physical mixture of clozapine and MMT, and clozapine nanoparticle-MMT nano-
composites at different loadings of clozapine (% (w/w)); (b) recrystallized curcumin (CUR), MMT, a 21.8% (w/w) physical mixture of curcumin and MMT, and
curcumin nanoparticle-MMT nanocomposites at different loadings of curcumin (% (w/w)); and (c) as received carbamazepine (CBMZ), MMT, a 33.3% (w/w)
physical mixture of carbamazepine and MMT, and carbamazepine nanoparticle-MMT nanocomposites at different loadings of carbamazepine (% (w/w)).
A. Kumar, et al. Colloids and Surfaces B: Biointerfaces 193 (2020) 111120
7
Fig. 5. DSC profiles of (a) as received clozapine (CLO), MMT, a 23% (w/w) physical mixture of clozapine and MMT and clozapine nanoparticle-MMT nanocomposites
at different loadings of clozapine (% (w/w)); (b) recrystallized curcumin (CUR), MMT, a 21.8% physical mixture of curcumin and MMT and curcumin nanoparticle-
MMT nanocomposites at different loadings of curcumin (% (w/w)); and (c) as received carbamazepine (CBMZ), MMT, a 33.3% physical mixture of carbamazepine
and MMT and carbamazepine nanoparticle-MMT nanocomposites at different loadings of carbamazepine (% (w/w)).
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endothermic peak was then observed at 193 ± 0.2 °C, which indicates
the melting of Form I in agreement with literature reports [34].
The physical mixtures of 23%, 21.8% and 33.3% (w/w) clozapine,
curcumin and carbamazepine respectively with MMT showed similar
thermograms to their as received and recrystallized forms. However, no
melting peak for clozapine or curcumin was observed for the CLO-MMT
or CUR-MMT nanocomposites with 23%, and 21.8% (w/w) loadings
respectively, pointing to an amorphous state of the clozapine and cur-
cumin nanoparticles within these nanocomposites (Fig. 5(a) and (b)).
An endothermic peak corresponding to the melting of carbamazepine
Form III was observed for the CBMZ-MMT nanocomposite when the
loading was increased to 33.3% (w/w), but with a much lower peak
area than that observed for the 33.3% (w/w) physical mixture of CBMZ
and MMT (Fig. 5(c)). Thus all the DSC measurements are in good
agreement with the PXRD measurements. No difference in PXRD and
DSC data were observed when PA was used in API-PA-MMT nano-
composites.
4. Discussion
Nanoparticles of three poorly water-soluble APIs (namely CLO, CUR
and CBMZ) were produced via reverse liquid antisolvent precipitation
and promptly stabilized in situ by adsorption onto bare (that is, un-
functionalized) MMT clay particles, affording API-MMT nanocomposite
solids that were easily isolatable via vacuum filtration. This approach
was used successfully to produce API-MMT nanocomposite solids with
various API loadings (% (w/w)). Solid state characterization of the
isolated nanocomposite solids via PXRD and DSC supports the view that
the APIs were predominantly present in amorphous forms. The API
dissolution profiles for these nanocomposite solids (at various API
loadings) were considerably better than the corresponding profiles for
the respective ‘as received’ crystalline APIs in terms of the rate of API
dissolved. Furthermore, CBMZ-MMT nanocomposite solids up to API
loadings of 33.3% (w/w) displayed dissolution profiles comparable
with that of a polymer-stabilized nanosuspension of CBMZ (30 nm
particle size); and CUR-MMT and CLO-MMT nanocomposite solids at
API loadings of 9% and 6.5% (w/w) respectively displayed dissolution
profiles that approached those of polymer-stabilized nanosuspensions
of CUR (173 nm particle size) and CLO (27 nm particle size) respec-
tively. When combined with the abovementioned PXRD and DSC
findings, the comparable nature of the dissolution profiles for these API-
MMT nanocomposite solids and their respective polymer-stabilized
nanosuspensions implies that the particle sizes of the APIs in the CUR-
MMT (9% (w/w) loading), CLO-MMT (6.5% (w/w) loading) and CBMZ-
MMT (33% (w/w) loading) nanocomposite solids are similar to the
nanoparticle sizes of CUR, CLO and CBMZ in their respective nano-
suspension [30,31]. As such, the authors contend that reverse liquid
antisolvent API precipitation in the presence of MMT (acting as an in
situ solid adsorbent stabilizer) offers a robust and straightforward
means of generating readily isolatable API-MMT nanocomposite solids.
However, when the CLO and CUR loading on MMT was increased to
23% and 21.8% respectively, the dissolution profiles deteriorated. The
poorer dissolution behavior of CLO and CUR at these higher loadings is
consistent with aggregation of the API nanoparticles on the MMT sur-
face, since these nanoparticle aggregates would have less available
surface area for dissolution. Therefore, in order to improve the dis-
solution profiles of CUR and CLO at higher loadings, the surface charge
of MMT was modified by the adsorption of a cationic protein protamine
(PA) prior to the antisolvent precipitation step. This was done ac-
cording to the procedure described in previous studies from our group
[30,31] to produce CUR-PA-MMT and CLO-PA-MMT nanocomposite
solids. The addition of protamine extends the range of loadings of CLO
and CUR at which fast (that is, nanosuspension-like) dissolution profiles
are maintained. 4.2mg of PA/g of MMT was found to be the optimum
PA coverage at which nanosuspension-like dissolution profiles were
preserved for CUR-PA-MMT and CLO-PA-MMT at 21.8% and 23% API
loadings respectively.
CLO and CUR likely attach to MMT’s negatively-charged surface via
hydrophobic interactions. It is hypothesized here that modifying this
surface with positively-charged PA generates charged adsorption sites
that facilitate an additional mode of attachment for the negatively-
charged CLO and CUR nanoparticles, namely via electrostatic interac-
tions. Therefore, the overall increase in available adsorption sites (hy-
drophobic and electrostatic) on the MMT surface allows a more
homogenous, segregated dispersion of negatively-charged API nano-
particles to adsorb to the functionalized MMT carrier, thus facilitating
the observed preservation of nanosuspension-like dissolution profiles at
the higher API loadings [30,31]. The zeta potentials of CLO and CUR
nanoparticles are -28.5 ± 2.5 and -33 ± 1.5mV respectively. Inter-
estingly, their dissolution behavior from MMT is comparable with
previous findings from our group where API nanoparticles with zeta
potentials in the range of -30 to −40mV only displayed enhanced
dissolution profiles at higher API loadings when PA surface coverages of
3–5mg/g MMT were used [30,31].
In a separate study, nanoparticles of dalcetrapib (DCP) were isolated
onto MMT up to 21% (w/w) but PA was not required to preserve an API
dissolution profile comparable with that of the DCP nanosuspension
[32]. Indeed, modifying MMT’s surface with PA made no meaningful
improvement to the DCP’s dissolution profile from the resulting nano-
composites. This is similar to the findings reported here for CBMZ.
CBMZ and DCP nanoparticles have similar zeta potentials: −13 ± 1.5
and −14 ± 2.5mV respectively. As such, the zeta potential of the API
appears to have a significant influence on the maximum API loading
that can be achieved on MMT while still preserving the dissolution
profile of polymer stabilized nanoparticles. When the zeta potential of
the API nanoparticles is more negative than about −25mV (for ex-
ample, in the cases of fenofibrate (-25.3 ± 0.9mV) [31], valsartan
(−42.5 ± 1.4mV) [30], clozapine (−28.5 ± 2.5mV) and curcumin
(−33 ± 1.5mV)) (Table 2) the dissolution properties of the corre-
sponding API nanocomposites deteriorate at API loadings above about
Table 2
Zeta potential measurements and particle sizes* for the nanoparticles of six APIs produced via antisolvent precipitation, and the corresponding maximum API
loadings on MMT and PA-MMT at which nanosuspension-like dissolution profiles are preserved.
API-MMT nanocomposite with
nanosuspension-like dissolution profile
API-PA-MMT nanocomposite with nanosuspension-
like dissolution profile
API Zeta potential of API
particles (mV)
Size of API particles*
(nm)




Fenofibrate [31] (FF) −25.3 ± 0.9 200−300 4.8 9 4.6
Clozapine (CLO) −28 ± 2.5 27 ± 0.5 6.5 23 4.2
Curcumin (CUR) −33 ± 1.5 173 ± 0.8 9 21.8 4.2
Valsartan [30] (Val) −42.5 ± 1.4 50 ± 0.4 20 33.3 3
Dalcetrapib [32] (DCP) −14 ± 2.5 429 ± 51 20.9 20.9 0
Carbamazepine (CBMZ) −13 ± 1.5 30 ± 0.5 33.3 33.3 0
* As polymer-stabilized nanosuspension.
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10% (w/w) (except for valsartan’s nanocomposites whose dissolution
properties deteriorated above 20% (w/w)). For these APIs, protamine
functionalization of MMT extends the loading ranges where nanosus-
pension-like dissolution profiles are preserved to 25–30% (w/w).
Table 2 shows the maximum achievable API loadings on MMT and PA-
MMT that preserved nanosuspension-like dissolution profiles. These
data suggest that in order to achieve nanosuspension-like dissolution
profiles for higher-loaded API nanocomposites, it is only necessary to
functionalise the MMT with PA when the zeta potential of the API
particles is more negative than ca. −25mV (Fig. 6).
Thus optimizing the balance between the zeta potentials of API
nanoparticles and MMT carrier particles is seen as an important factor
in preserving the nanosuspension-like dissolution profiles for higher-
loaded API nanocomposites.
5. Conclusion
In conclusion, nanoparticles of clozapine (27 nm), curcumin
(173 nm) and carbamazepine (30 nm) with zeta potential
−28.5 ± 2.5, −33 ± 1.5 and −13 ± 1.5mV respectively were
successfully stabilized and isolated onto montmorillonite (MMT) carrier
particles. Nanosuspension-like dissolution profiles were preserved for
these APIs from the resulting nanocomposite solids up to API loadings
of 23%, 21.8% and 33.3% (w/w) respectively, although prior functio-
nalization of MMT’s surface with protamine (PA) was necessary to
achieve this in the cases of clozapine and curcumin. As such, the dis-
solution profiles of these nanoparticles from their respective MMT/PA-
MMT nanocomposites were shown to be influenced by parameters such
as the zeta potential of the API nanoparticles, the degree of PA func-
tionalization and the API loading on the carrier particle system. API
nanoparticles with zeta potentials more negative than ca. –25mV re-
quired the MMT surface to be functionalized with PA in order to pre-
serve nanosuspension-like dissolution profiles at higher API loadings;
when so required, the optimal PA loading was consistently around
4mg/g of MMT. PA likely limited API nanoparticle aggregation by
improving MMT’s adsorptive characteristics and thus facilitated the
enhanced dissolution profiles of these API nanoparticles at higher
loadings from the dried state. By contrast, API nanoparticles with zeta
potentials less negative than ca. –25mV did not require the MMT
modification with PA in order to maintain enhanced dissolution profiles
at high API loadings.
This method of carrier particle mediated stabilization and isolation
of API nanoparticles offers a potentially viable means of producing a
fast dissolving, solid dosage form for poorly water soluble APIs, where
the surface properties of the carrier particle can be effectively modified
with prior knowledge of the API’s zeta potential.
CRediT authorship contribution statement
Ajay Kumar: Investigation, Methodology, Writing - original draft.
Benjamin K. Hodnett: Funding acquisition, Conceptualization,
Supervision, Writing - review & editing. Sarah Hudson:
Conceptualization, Supervision, Writing - review & editing. Peter
Davern: Conceptualization, Supervision, Writing - original draft,
Writing - review & editing.
Declaration of Competing Interest
The authors declare no competing financial interest.
Acknowledgements
This publication has emanated from research conducted with the
financial support of the Synthesis and Solid State Pharmaceutical
Centre, funded by Science Foundation of Ireland (SFI) under grant
numbers 12/RC/2275 and 15/US-C2C/13133, as well as support from
the Bernal Institute, and the Department of Chemical Sciences at the
University of Limerick.
Appendix A. Supplementary data
Supplementary material related to this article can be found, in the
online version, at doi:https://doi.org/10.1016/j.colsurfb.2020.111120.
References
[1] M.R. Gigliobianco, C. Casadidio, R. Censi, P. Di Martino, Nanocrystals of poorly
soluble drugs: drug bioavailability and physicochemical stability, Pharmaceutics 10
(3) (2018).
[2] T. Loftsson, M.E. Brewster, Pharmaceutical applications of cyclodextrins: basic
science and product development, J. Pharm. Pharmacol. 62 (11) (2010)
1607–1621.
[3] A. Tuomela, J. Hirvonen, L. Peltonen, Stabilizing agents for drug nanocrystals: ef-
fect on bioavailability, Pharmaceutics 8 (2) (2016) 16.
[4] G.L. Amidon, H. Lennernäs, V.P. Shah, J.R. Crison, A theoretical basis for a bio-
pharmaceutic drug classification: the correlation of in vitro drug product dissolu-
tion and in vivo bioavailability, Pharm. Res. 12 (3) (1995) 413–420.
[5] P. Khadka, J. Ro, H. Kim, I. Kim, J.T. Kim, H. Kim, J.M. Cho, G. Yun, J. Lee,
Pharmaceutical particle technologies: an approach to improve drug solubility,
dissolution and bioavailability, Asian J. Pharm. Sci. 9 (6) (2014) 304–316.
[6] U. Wais, A.W. Jackson, T. He, H. Zhang, Nanoformulation and encapsulation ap-
proaches for poorly water-soluble drug nanoparticles, Nanoscale 8 (4) (2016)
Fig. 6. The influence of PA’s presence (red □) and absence
(black ◆) on the initial dissolution rates of API nanoparticles
with different zeta potentials from their respective API nano-
composites at the following maximum achieved API loadings
(% (w/w)): Val (33.3%), CUR (21.8%), CLO (23%), FF (9%),
CBMZ (33.3%) and DCP (20.9%) (For interpretation of the
references to colour in this figure legend, the reader is referred
to the web version of this article).
A. Kumar, et al. Colloids and Surfaces B: Biointerfaces 193 (2020) 111120
10
1746–1769.
[7] Y. Kawabata, K. Wada, M. Nakatani, S. Yamada, S. Onoue, Formulation design for
poorly water-soluble drugs based on biopharmaceutics classification system: basic
approaches and practical applications, Int. J. Pharm. 420 (1) (2011) 1–10.
[8] R. Thakuria, A. Delori, W. Jones, M.P. Lipert, L. Roy, N. Rodríguez-Hornedo,
Pharmaceutical cocrystals and poorly soluble drugs, Int. J. Pharm. 453 (1) (2013)
101–125.
[9] C.L.-N. Vo, C. Park, B.-J. Lee, Current trends and future perspectives of solid dis-
persions containing poorly water-soluble drugs, Eur. J. Pharm. Biopharm. 85 (3)
(2013) 799–813.
[10] Y. Lu, K. Park, Polymeric micelles and alternative nanonized delivery vehicles for
poorly soluble drugs, Int. J. Pharm. 453 (1) (2013) 198–214.
[11] H. Mu, R. Holm, A. Müllertz, Lipid-based formulations for oral administration of
poorly water-soluble drugs, Int. J. Pharm. 453 (1) (2013) 215–224.
[12] G. Kaptay, On the size and shape dependence of the solubility of nano-particles in
solutions, Int. J. Pharm. 430 (1–2) (2012) 253–257.
[13] A.T. Florence, T. Alexander, D. Attwood, Physicochemical Principles of Pharmacy,
Manufacture, Formulation, and Clinical Use, 2020.
[14] A.A. Noyes, W.R. Whitney, The rate of solution of solid substances in their own
solutions, J. Am. Chem. Soc. 19 (12) (1897) 930–934.
[15] W. Ostwald, Über die vermeintliche isomerie des roten und gelben quecksilber-
oxyds und die Oberflächenspannung fester körper, Z. Phys. Chem./Int. J. Res. Phys.
Chem. Chem. Phys. 34U (1) (1900).
[16] G. Nykamp, U. Carstensen, B.W. Müller, Jet milling–a new technique for micro-
particle preparation, Int. J. Pharm. 242 (1–2) (2002) 79–86.
[17] H.D. Williams, N.L. Trevaskis, S.A. Charman, R.M. Shanker, W.N. Charman,
C.W. Pouton, C.J.H. Porter, Strategies to address low drug solubility in discovery
and development, Pharmacol. Rev. 65 (1) (2013) 315–499.
[18] M. Nakach, J.-R. Authelin, A. Chamayou, J. Dodds, Comparison of various milling
technologies for grinding pharmaceutical powders, Int. J. Miner. Process. 74 (2004)
S173–S181.
[19] C. KECK, R. MULLER, Drug nanocrystals of poorly soluble drugs produced by high
pressure homogenisation, Eur. J. Pharm. Biopharm. 62 (1) (2006) 3–16.
[20] K. Satoshi, M. Akira, K. Shigetaka, M. Yukiyoshi, Effect of grinding on the solid-state
stability of cefixime trihydrate, Int. J. Pharm. (1989).
[21] J.O. Waltersson, P. Lundgren, The effect of mechanical comminution on drug sta-
bility, Acta Pharm. Suec. 22 (5) (1985) 291–300.
[22] L. Wu, J. Zhang, W. Watanabe, Physical and chemical stability of drug nano-
particles, Adv. Drug Deliv. Rev. 63 (6) (2011) 456–469.
[23] B. Sinha, R.H. Müller, J.P. Möschwitzer, Bottom-up approaches for preparing drug
nanocrystals: formulations and factors affecting particle size, Int. J. Pharm. 453 (1)
(2013) 126–141.
[24] M.E. Matteucci, M.A. Hotze, K.P. Johnston, R.O. Williams, Drug nanoparticles by
antisolvent precipitation: mixing energy versus surfactant stabilization, Langmuir
22 (21) (2006) 8951–8959.
[25] N. Rasenack, B.W. Müller, Micron-size drug particles: common and novel micro-
nization techniques, Pharm. Dev. Technol. 9 (1) (2004) 1–13.
[26] Y. Liu, K. Kathan, W. Saad, R.K. Prud’homme, Ostwald ripening of β-Carotene na-
noparticles, Phys. Rev. Lett. 98 (3) (2007) 036102.
[27] E.M. Merisko-Liversidge, G.G. Liversidge, Drug nanoparticles: formulating poorly
water-soluble compounds, Toxicol. Pathol. 36 (1) (2008) 43–48.
[28] J. Hu, W.K. Ng, Y. Dong, S. Shen, R.B.H. Tan, Continuous and scalable process for
water-redispersible nanoformulation of poorly aqueous soluble APIs by antisolvent
precipitation and spray-drying, Int. J. Pharm. (2011).
[29] Hydrosols - alternatives for the parenteral application of poorly water soluble drugs,
Eur. J. Pharm. Biopharm. (1994).
[30] A. Kumar, P. Davern, B.K. Hodnett, S.P. Hudson, Carrier particle mediated stabili-
zation and isolation of valsartan nanoparticles, Colloids Surf. B Biointerfaces 175
(2019) 554–563.
[31] T. Tierney, K. Bodnár, Å. Rasmuson, S. Hudson, Carrier particle design for stabili-
zation and isolation of drug nanoparticles, Int. J. Pharm. 518 (1–2) (2017)
111–118.
[32] K. Bodnár, S.P. Hudson, Å.C. Rasmuson, Drug loading and dissolution properties of
dalcetrapib – montmorillonite nanocomposite microparticles, Org. Process Res.
Dev. (2020).
[33] R.J. Hunter, Foundations of Colloid Science, Oxford University Press, 2001.
[34] A.L. Grzesiak, M. Lang, K. Kim, A.J. Matzger, Comparison of the four anhydrous
polymorphs of carbamazepine and the crystal structure of form I, J. Pharm. Sci. 92
(11) (2003) 2260–2271.
A. Kumar, et al. Colloids and Surfaces B: Biointerfaces 193 (2020) 111120
11
